THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

IVAX Corporation (Retired) (IVX.X)

5/2/2005 Proxy Information

We paid approximately $2,436,000 to PharmAir Corporation for business use of an airplane in 2004 and intend to make additional payments to PharmAir for business use of the airplane in 2005. PharmAir is indirectly beneficially owned by Dr. Frost.

During 2004, a wholly-owned subsidiary of IVAX entered into a promotion agreement with Aero Pharmaceuticals, Inc., pursuant to which certain sales representatives of Aero will promote designated products of IVAX. Under the terms of the agreement, we paid Aero a promotion fee of $683,000 for the year ended December 31, 2004. The agreement has an 18-month term, subject to our right to terminate the agreement on 30 days notice prior to each of October 8, 2005 and January 8, 2006. Mr. Richard Frost, the Chairman and a principal shareholder of Aero, is the nephew of Dr. Frost. Dr. Frost has no stock ownership or other financial interest in Aero.

During February 2005, a wholly-owned subsidiary of IVAX entered into two agreements with InnovaPharm, Inc. Pursuant to the first agreement which relates to prescription pharmaceutical products, InnovaPharm will provide services and perform certain regulatory functions in Canada with respect to certain designated products. Under the agreement, we will pay InnovaPharm a fee based on a percentage of net sales for these services. The term of the agreement began upon execution of the agreement and continues through June 30, 2007 with automatic two-year renewals, subject to our right to terminate the agreement on 120 days notice prior to each anniversary of the agreement’s execution date. Pursuant to the second agreement which relates to OTC products InnovaPharm will serve as an exclusive sales representative in Canada for the promotion of certain designated OTC products. Under the agreement, we will pay InnovaPharm a fee based on a percentage of net sales for these services. The agreement has a three-year term, with one-year renewals upon written consent of the parties. Mr. Tarik Henein, the President and a principal shareholder of InnovaPharm, is the son of Dr. Rafick Henein, our Senior Vice President and President and CEO of IVAX Pharmaceuticals, Inc. Dr. Henein has no stock ownership or other financial interest in InnovaPharm.

4/29/2004 Proxy Information

During 2003, Whitman Education Group, Inc. leased approximately 11,567 square feet of office space from us in Miami, Florida at an annual rental of $292,000. Whitman was acquired by an unaffiliated entity, Career Education Corporation on July 1, 2003. Following the acquisition, the lease was terminated and Whitman is to vacate the facility no later than May 31, 2004. Prior to the acquisition, Dr. Frost, our Chairman of the Board of Directors and Chief Executive Officer, was Chairman of the Board of Directors of Whitman. Mr. Flanzraich, our Vice Chairman, President and a Director, was a Director of Whitman, and Mr. Pfenniger, one of our Directors, was Chief Executive Officer and Vice Chairman of the Board of Directors of Whitman. In addition Dr. Frost was a principal shareholder of Whitman.

We paid approximately $2,500,000 to PharmAir Corporation for use of an airplane in 2003 and intend to make additional payments to PharmAir for use of the airplane in 2004. PharmAir is indirectly beneficially owned by Dr. Frost.

Jack Fishman served as Chief Scientific Officer of Ivax Corporation from 1991 to 1995, as Vice Chairman from 1991 to 1997 and as President from 1988 to 1991.

Whitman Education Group, Inc. leases approximately 13,849 square feet of office space from us in Miami, Florida at an annual rental of $290,531. The lease may be terminated by either party upon 180 days notice. Dr. Frost, our Chairman of the Board of Directors and Chief Executive Officer, is Chairman of the Board of Directors of Whitman. Mr. Flanzraich, our Vice Chairman, President and a Director, is a director of Whitman. Richard C. Pfenniger, Jr., one of our directors, is Chief Executive Officer and Vice Chairman of the Board of Directors of Whitman. In addition, Dr. Frost is a principal shareholder of Whitman.

4/30/2003 Proxy Information

Whitman Education Group, Inc. leases approximately 13,849 square feet of office space from us in Miami, Florida at an annual rental of $290,531. The lease may be terminated by either party upon 180 days notice. Dr. Frost, our Chairman of the Board of Directors and Chief Executive Officer, is Chairman of the Board of Directors of Whitman. Mr. Flanzraich, our Vice Chairman, President and a Director, is a director of Whitman. Richard C. Pfenniger, Jr., one of our directors, is Chief Executive Officer and Vice Chairman of the Board of Directors of Whitman. In addition, Dr. Frost is a principal shareholder of Whitman.

We paid approximately $2,700,000 to PharmAir Corporation (“PharmAir”) for use of an airplane in 2002 and intend to make additional payments to PharmAir for use of the airplane in 2003. PharmAir is indirectly beneficially owned by Dr. Frost.